Agoracom

MONTREAL, June 13 - Haemacure Corporation (TSX : HAE), a
Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announced today that Joseph Galli, Chairman and Chief Executive Officer, will present Haemacure and give an update on the Company's major milestone achievements at the Bio International Convention - The Global Event for Biotechnology. The presentation will take place on Thursday, June 19th, at 1:30 pm (PDT), in Room 3, of the San Diego Convention Centre.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase
III clinical trials during the first quarter of 2009. Haemacure's second
product candidate is thrombin, a component of its fibrin sealant, now in
preclinical stage. Follow-on development will focus on surgical hemostats,
wound healing, adhesion prevention, regenerative medecine, drug delivery and
combination with biomaterials. Haemacure has discovered eleven additional
specialty proteins and enzymes in one if its two plasma fractions and seeks to
advance these proteins and enzymes through partnerships with pharmaceutical
and biotechnology companies. Haemacure operates offices in Sarasota, Florida
through a wholly-owned subsidiary. The Corporation is traded under stock
symbol HAE on the TSX.

For further information:

Haemacure Corporation:

Joseph Galli
Chairman and CEO
(514) 990-7074
jgalli@haemacure.ca
www.haemacure.com

Diane Roch,
Director, Communications
(514) 282-3350 ext. 27,
Cell.: (514) 952-3350,
droch@haemacure.ca/